Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Quantum Genomics Biopharma developing cardiovascular treatments, now in judicial liquidation.	France	ALQGC
QuidelOrtho Corp Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.	United States of America	QDEL
Quince Therapeutics, Inc. Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.	United States of America	QNCX
Quoin Pharmaceuticals, Ltd. Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.	United States of America	QNRX
Quratis Inc. Develops infectious disease vaccines and offers biologics CDMO services for global health.	South Korea	348080
Radiopharm Theranostics Ltd Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.	United States of America	RADX
Rallybio Corp Develops therapies for severe and rare diseases in hematology and complement dysregulation.	United States of America	RLYB
Rani Therapeutics Holdings, Inc. Develops a capsule to convert injectable biologics into oral pills for chronic diseases.	United States of America	RANI
Rapport Therapeutics, Inc. Developing precision small molecule medicines for Central Nervous System (CNS) disorders.	United States of America	RAPP
RAPT Therapeutics, Inc. Developing immune-targeting therapies for inflammatory and immunologic diseases.	United States of America	RAPT